Cancer, Colorectal cancer , Gastrointestinal stromal tumors
IMCRImmunocore HoldingsCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for IMC-R117C [PIWIL1-A02 targeted] in Cancer, Colorectal cancer , Gastrointestinal stromal tumors. The expected timing is based on the latest available company guidance and may change.
12/17/24- First patient dosed in Ph1/2 trial. 2/26/25- Trial ongoing. 11/06/25:- Phase 1/2 IMC-R117C dose escalation trial enrolling advanced colorectal and other GI cancers, as monotherapy and with standard therapies. 02/25/26:- IMC-R117C Phase 1/2 colorectal and GI tumor trial enrolling; company expects to present initial data in 2027. 05/06/26:- IMC-R117C Ph1/2 colorectal and GI tumor dose escalation trial enrolling; company still expects initial data in 2027. 08/06/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.